a good company update, page-2

My spin;

1. Research interest in peptide libraries was getting so big they had to set up the Cambridge option.

2.Big Pharma patent expiry cliff/lack of blockbuster drugs- already well known providing external opportunities with companies like PYC.

3. Billions of "options" generated a process to speed up analysis from years to weeks.

4.New Discussions gathering momentum- anyone know which Pharma Company based in La Jolla, San Diego - sounds like clue.

Might have been a good decision to buy PYCO this morning. Sounds like a break out year 2011.

Thoughts everyone?

Ramses